Achieve Life Sciences Inc. Common Shares (ACHV)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering this late-stage biotech at $7.00 a share, a $220.4 million market value, based on the close on 2026-10-13. I see no revenue in the filed reports. The losses are large and recurring: a net loss of $10.2 million in fiscal Q1 2026, the quarter ended 2026-03-31, then $74.8 million in fiscal Q2 2026, the quarter ended 2026-06-30; fiscal 2025, the year ended 2025-12-31, lost $54.6 million; fiscal 2024, the year ended 2024-12-31, lost $39.8 million; and fiscal 2023, the year ended 2023-12-31, lost $29.8 million. TTM free cash flow is negative $47.2 million, a negative 21.4% free cash flow yield, so the company consumes cash. The balance sheet shows debt-to-equity of 1.40, and FairStock calculations give a Piotroski F-Score of 1/9 and an Altman Z-Score of -1.95, signs of financial fragility. ROE of -844.99% and ROCE of -29.21% reflect no profitable capital. Valuation is not grounded in earnings: FairStock's P/E is -4.22 and P/B is 26.45. The business may have a product candidate in cytisinicline for nicotine independence, with license and supply agreements with Sopharma AD and University of Bristol. But without revenue, any moat depends on clinical and regulatory success, not demonstrated economic advantage. Growth is only growth in losses; profit growth is -487.90%. FairStock Score is 13/100, and the computed Lynch category is none because of losses in each of the last four years. This is speculative. Graham would demand a margin of safety; here intrinsic value is hard to calculate and the price pays for future hope. As an educational matter, the numbers show a fragile, cash-burning enterprise.

In plain English: Achieve Life Sciences is a small drug company developing cytisinicline, a treatment intended to help people stop using nicotine. It has no reported revenue and has been losing money, including a $74.8 million loss in fiscal Q2 2026, the quarter ended June 30, 2026. At $7.00 on October 13, 2026, the price looks expensive relative to its losses and accounting value, and the overall financial picture is weak.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer